Press Releases

 

Financial

  Date Title and Summary View
Jun 22, 2017
LAWRENCEVILLE, N.J., June 22, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (the "Company") (NASDAQ:CLSN) today announced that it has cancelled the registered direct offering of common stock announced Monday, June 19, 2017. The Company had entered into security purchase agreements with three institutional investors to purchase shares of common sto...
Jun 19, 2017
LAWRENCEVILLE, N.J., June 19, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (the "Company") (NASDAQ:CLSN) today announced that it has entered into definitive agreements with several institutional investors to purchase an aggregate of approximately $5.4 million of shares of common stock, or pre-funded warrants in lieu thereof, in a registered direc...
Jun 14, 2017
LAWRENCEVILLE, N.J., June 14, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today announced that it received notice from The NASDAQ Stock Market LLC (NASDAQ) on June 13, 2017 indicating that the Company has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550...
May 26, 2017
LAWRENCEVILLE, N.J., May 26, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, announced today that it is effecting a 1 for 14 reverse stock split of its common stock which will be effective for trading purposes as of the commencement of trading on Tuesday, May 30, 2017.  As of that date, each fourt...
May 12, 2017
LAWRENCEVILLE, N.J., May 12, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today announced financial results for the quarter ended March 31, 2017 and provided an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-...
May 5, 2017
LAWRENCEVILLE, N.J., May 05, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended March 31, 2017 and provide an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxo...
Mar 16, 2017
LAWRENCEVILLE, N.J., March 16, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today announced financial results for the year ended December 31, 2016 and provided an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GE...
Mar 9, 2017
LAWRENCEVILLE, N.J., March 09, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) announced today that the Company will host a conference call to discuss year-end 2016 financial results and provide an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-1, an...
Feb 15, 2017
LAWRENCEVILLE, N.J., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (the "Company") (NASDAQ:CLSN) today announced the pricing of a public offering with expected total gross proceeds of approximately $5.0 million. The offering was priced at $0.23 per share of common stock (or common stock equivalent), with each share of common stock (o...
Dec 20, 2016
LAWRENCEVILLE, N.J., Dec. 20, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (the "Company") (NASDAQ:CLSN) today announced that it has entered into a definitive agreement with several institutional investors to purchase an aggregate of approximately $1.8 million of shares of common stock in a registered direct offering. The Company agreed to...
Page:
1
... NextLast
= add release to Briefcase
Share This